Search

Your search keyword '"Dorresteijn E"' showing total 19 results
Start Over Author "Dorresteijn E"
19 results on '"Dorresteijn E"'

1. Uncovering risk factors for kidney injury in children with a solitary functioning kidney

Author

Beeren, M.C.G., Blokland-Loggers, H.E., Breukels, M., van den Broek, L.M., del Canho, R., Creemers, D., van Dael, C.M.L., van der Deure, H., Dings-Lammertink, A., Dorrepaal, C., Dorresteijn, E., Feitz, W.F.J., Gracchi, V., Groen in ‘t Woud, S., Harnisch, E., Jacobs, M.J., Jira, P.E., Keijzer-Veen, M.G., Kloosterman, F.J., Knots, E., Konijnenberg, A.Y., Koppejan-Stapel, M., van der Kuur, E.C., van Ledden-Klok, M.J., Leunissen, R.W.J., Lilien, M.R., Jansen, C. Meine, de Moor, R., Nijhuis, I.J.M., Pierik, L.J.W.M., Pijning, A., de Pont, S.M.H.B., Renkema, K.Y., Rijlaarsdam, R., Roeleveld, N., van Rooij, R.W.G., Schreuder, M.F., Semmekrot, B., Steffens, M.G., Tanja, A.L., Westland, R., van Wijk, J.A.E., Wijnands - van den Berg, E., van der Zanden, L.F.M., Zegers, B., Groen in ‘t Woud, Sander, Roeleveld, Nel, Westland, Rik, Renkema, Kirsten Y., Steffens, Martijn G., Gracchi, Valentina, Lilien, Marc R., van Wijk, Joanna A.E., Feitz, Wout F.J., Schreuder, Michiel F., and van der Zanden, Loes F.M.

Published
2023
Full Text
View/download PDF

2. Dehydratie en water- en zouthuishouding

Author

de Laat, P. C. J., Dorresteijn, E. M., Bosman, D. K., Derksen-Lubsen, G., editor, Moll, H.A., editor, Oudesluys-Murphy, A.M., editor, Sprij, A.J., editor, Bolt-Wieringa, J.W., editor, van den Elzen, A.P.M., editor, Leeuwenburgh-Pronk, W.G., editor, Ropers, F.G., editor, and Verhoeven, J.J., editor

Published
2018
Full Text
View/download PDF

3. Uncovering risk factors for kidney injury in children with a solitary functioning kidney

Author

Groen in ‘t Woud, Sander, primary, Roeleveld, Nel, additional, Westland, Rik, additional, Renkema, Kirsten Y., additional, Steffens, Martijn G., additional, Gracchi, Valentina, additional, Lilien, Marc R., additional, van Wijk, Joanna A.E., additional, Feitz, Wout F.J., additional, Schreuder, Michiel F., additional, van der Zanden, Loes F.M., additional, Beeren, M.C.G., additional, Blokland-Loggers, H.E., additional, Breukels, M., additional, van den Broek, L.M., additional, del Canho, R., additional, Creemers, D., additional, van Dael, C.M.L., additional, van der Deure, H., additional, Dings-Lammertink, A., additional, Dorrepaal, C., additional, Dorresteijn, E., additional, Feitz, W.F.J., additional, Gracchi, V., additional, Groen in ‘t Woud, S., additional, Harnisch, E., additional, Jacobs, M.J., additional, Jira, P.E., additional, Keijzer-Veen, M.G., additional, Kloosterman, F.J., additional, Knots, E., additional, Konijnenberg, A.Y., additional, Koppejan-Stapel, M., additional, van der Kuur, E.C., additional, van Ledden-Klok, M.J., additional, Leunissen, R.W.J., additional, Lilien, M.R., additional, Jansen, C. Meine, additional, de Moor, R., additional, Nijhuis, I.J.M., additional, Pierik, L.J.W.M., additional, Pijning, A., additional, de Pont, S.M.H.B., additional, Renkema, K.Y., additional, Rijlaarsdam, R., additional, Roeleveld, N., additional, van Rooij, R.W.G., additional, Schreuder, M.F., additional, Semmekrot, B., additional, Steffens, M.G., additional, Tanja, A.L., additional, Westland, R., additional, van Wijk, J.A.E., additional, Wijnands - van den Berg, E., additional, van der Zanden, L.F.M., additional, and Zegers, B., additional

Published
2023
Full Text
View/download PDF

4. Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective

Author

Bouwmeester, R.N., Duineveld, C., Wijnsma, K.L., Bemelman, F.J., Heijden, J.W. van der, Wijk, J.A.E. van, Bouts, A.H.M., Wetering, J. van de, Dorresteijn, E., Berger, S.P., Gracchi, V., Zuilen, A.D. van, Keijzer-Veen, M.G., Vries, A.P.J. de, Rooij, R.W.G. van, Engels, F.A.P.T., Altena, W., Wildt, R. de, Kempen, E. van, Adang, E.M., Avest, M. ter, Heine, R. ter, Volokhina, E.B., Heuvel, L.P.W.J. van den, Wetzels, J.F.M., Kar, N.C.A.J. van de, Nephrology, Pediatrics, ACS - Microcirculation, Amsterdam Reproduction & Development (AR&D), Kindergeneeskunde, MUMC+: MA Medische Staf Kindergeneeskunde (9), RS: FHML non-thematic output, Internal Medicine, Paediatric Nephrology, ARD - Amsterdam Reproduction and Development, Groningen Kidney Center (GKC), and Groningen Institute for Organ Transplantation (GIOT)

Subjects
MUTATIONS, atypical hemolytic uremic syndrome, eculizu-mab, DISCONTINUATION, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], thrombotic microangiopathy, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Nephrology, complement inhibition, eculizumab, complement, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], COMPLEMENT ACTIVATION, cost-effectiveness, AHUS
Abstract

Introduction: The introduction of eculizumab has improved the outcome in patients with atypical hemo-lytic uremic syndrome (aHUS). The optimal treatment strategy is debated. Here, we report the results of the CUREiHUS study, a 4-year prospective, observational study monitoring unbiased eculizumab discontinuation in Dutch patients with aHUS after 3 months of therapy. Methods: All pediatric and adult patients with aHUS in native kidneys and a first-time eculizumab treat-ment were evaluated. In addition, an extensive cost-consequence analysis was conducted. Results: A total of 21 patients were included in the study from January 2016 to October 2020. In 17 patients (81%), a complement genetic variant or antibodies against factor H were identified. All patients showed full recovery of hematological thrombotic microangiopathy (TMA) parameters after the start of eculizumab. A renal response was noted in 18 patients. After a median treatment duration of 13.6 weeks (range 2.1-43.9), eculizumab was withdrawn in all patients. During follow-up (80.7 weeks [0.0-236.9]), relapses occurred in 4 patients. Median time to first relapse was 19.5 (14.3-53.6) weeks. Eculizumab was reinitiated within 24 hours in all relapsing patients. At last follow-up, there were no chronic sequelae, i.e., no clinically relevant increase in serum creatinine (sCr), proteinuria, and/or hypertension in relapsing patients. The low sample size and event rate did not allow to determine predictors of relapse. However, relapses only occurred in patients with a likely pathogenic variant. The cost-effectiveness analysis revealed that the total medical expenses of our population were only 30% of the fictive expenses that would have been made when patients received eculizumab every fortnight. Conclusion: It is safe and cost-effective to discontinue eculizumab after 3 months of therapy in patients with aHUS in native kidneys. Larger data registries are needed to determine factors associated with suboptimal kidney function recovery during eculizumab treatment, factors to predict relapses, and long-term outcomes of eculizumab discontinuation.

Published
2022

5. Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study

Author

Bouwmeester, R.N., Duineveld, C., Wijnsma, K.L., Bemelman, F.J., Heijden, J.W. van der, Wijk, J.A. van, Bouts, A.H., Wetering, J. van de, Dorresteijn, E., Berger, S.P., Adang, E.M., Avest, M. ter, Heine, R. ter, Volokhina, E.B., Heuvel, L.P.W.J. van den, Wetzels, J.F.M., Kar, N.C.A.J. van de, Bouwmeester, R.N., Duineveld, C., Wijnsma, K.L., Bemelman, F.J., Heijden, J.W. van der, Wijk, J.A. van, Bouts, A.H., Wetering, J. van de, Dorresteijn, E., Berger, S.P., Adang, E.M., Avest, M. ter, Heine, R. ter, Volokhina, E.B., Heuvel, L.P.W.J. van den, Wetzels, J.F.M., and Kar, N.C.A.J. van de

Abstract

Item does not contain fulltext

Published
2022

6. Groene Hotspot Houten : jaarverslag 2019

Author

Westerveld, T., Dorresteijn, E., Ouderkerken, S., Kamerling, H., Westerveld, T., Dorresteijn, E., Ouderkerken, S., and Kamerling, H.

Published
2020

7. REducing STEroids in Relapsing Nephrotic syndrome: the RESTERN study— protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study

Author

Schijvens, A M, primary, Dorresteijn, E M, additional, Roeleveld, N, additional, ter Heine, R, additional, van Wijk, J A E, additional, Bouts, A H M, additional, Keijzer-Veen, M G, additional, van de Kar, N C A J, additional, van den Heuvel, L P W J, additional, and Schreuder, M F, additional

Published
2017
Full Text
View/download PDF

10. Diagnose in beeld (272). Een jongen met verkleurde, pijnlijke handen

Author

Bekkali, N., Niemantsverdriet, M. B. A., Dorresteijn, E. M., and Paediatric Gastroenterology

Abstract

A 6-year-old boy was admittted because of dark discoloured and painful finger tips of both hands, which had developed 2 weeks after playing with bare hands in a ditch with cold water still containing parts of ice. Trench foot of the hands was diagnosed

Published
2006

12. AKI - Clinical

Author

Gok Oguz, E., primary, Olmaz, R., additional, Turgutalp, K., additional, Muslu, N., additional, Sungur, M. A., additional, Kiykim, A., additional, Van Biesen, W., additional, Vanmassenhove, J., additional, Glorieux, G., additional, Vanholder, R., additional, Chew, S., additional, Forster, K., additional, Kaufeld, T., additional, Kielstein, J., additional, Schilling, T., additional, Haverich, A., additional, Haller, H., additional, Schmidt, B., additional, Hu, P., additional, Liang, X., additional, Chen, Y., additional, LI, R., additional, Jiang, F., additional, LI, Z., additional, Shi, W., additional, Lim, C. C. W., additional, Chia, C. M. L., additional, Tan, A. K., additional, Tan, C. S., additional, Ng, R., additional, Subramani, S., additional, Perez de Jose, A., additional, Bernis Carro, C., additional, Madero Jarabo, R., additional, Bustamante, J., additional, Sanchez Tomero, J. A., additional, Chung, W., additional, Ro, H., additional, Chang, J. H., additional, Lee, H. H., additional, Jung, J. Y., additional, Fazzari, L., additional, Giuliani, A., additional, Scrivano, J., additional, Pettorini, L., additional, Benedetto, U., additional, Luciani, R., additional, Roscitano, A., additional, Napoletano, A., additional, Coclite, D., additional, Cordova, E., additional, Punzo, G., additional, Sinatra, R., additional, Mene, P., additional, Pirozzi, N., additional, Shavit, L., additional, Manilov, R., additional, Algur, N., additional, Wiener-Well, Y., additional, Slotki, I., additional, Pipili, C., additional, Vrettou, C. S., additional, Avrami, K., additional, Economidou, F., additional, Glynos, K., additional, Ioannidou, S., additional, Markaki, V., additional, Douka, E., additional, Nanas, S., additional, De Pascalis, A., additional, Cofano, P., additional, Proia, S., additional, Valletta, A., additional, Vitale, O., additional, Russo, F., additional, Buongiorno, E., additional, Filiopoulos, V., additional, Biblaki, D., additional, Lazarou, D., additional, Chrysis, D., additional, Fatourou, M., additional, Lafoyianni, S., additional, Vlassopoulos, D., additional, Zakiyanov, O., additional, Kriha, V., additional, Vachek, J., additional, Svarcova, J., additional, Zima, T., additional, Tesar, V., additional, Kalousova, M., additional, Kaushik, M., additional, Ronco, C., additional, Cruz, D., additional, Zhang, L., additional, Zhang, W., additional, Chen, N., additional, Ejaz, A. A., additional, Kambhampati, G., additional, Ejaz, N., additional, Dass, B., additional, Lapsia, V., additional, Arif, A. A., additional, Asmar, A., additional, Shimada, M., additional, Alsabbagh, M., additional, Aiyer, R., additional, Johnson, R., additional, Chen, T.-H., additional, Chang, C.-H., additional, Chang, M.-Y., additional, Tian, Y.-C., additional, Hung, C.-C., additional, Fang, J.-T., additional, Yang, C.-W., additional, Chen, Y.-C., additional, Cantaluppi, V., additional, Quercia, A. D., additional, Figliolini, F., additional, Giacalone, S., additional, Pacitti, A., additional, Gai, M., additional, Guarena, C., additional, Leonardi, G., additional, Biancone, L., additional, Camussi, G., additional, Segoloni, G. P., additional, De Cal, M., additional, Lentini, P., additional, Clementi, A., additional, Virzi, G. M., additional, Scalzotto, E., additional, Lacquaniti, A., additional, Donato, V., additional, Fazio, M. R., additional, Lucisano, S., additional, Cernaro, V., additional, Lupica, R., additional, Buemi, M., additional, Helvaci, I., additional, Anik, E., additional, Wani, M., additional, Wani, D. I., additional, Bhat, D. M. A., additional, Banday, D. K., additional, Najar, D. M. S., additional, Reshi, D. A. R., additional, Palla, D. N. A., additional, Iglesias, P., additional, Olea, T., additional, Vega-Cabrera, C., additional, Heras, M., additional, Bajo, M. A., additional, Del Peso, G., additional, Arias, M. J., additional, Selgas, R., additional, Diez, J. J., additional, Daher, E., additional, Costa, P. L., additional, Pereira, E. N. S., additional, Santos, R. D. P., additional, Abreu, K. L., additional, Silva Junior, G., additional, Pereira, E. D. B., additional, Raimundo, M., additional, Crichton, S., additional, Syed, Y., additional, Martin, J., additional, Whiteley, C., additional, Bennett, D., additional, Ostermann, M., additional, Gjyzari, A., additional, Thereska, N., additional, Koroshi, A., additional, Barbullushi, M., additional, Kodra, S., additional, Idrizi, A., additional, Strakosha, A., additional, Petrela, E., additional, Lemmich Smith, J., additional, Klimenko, A., additional, Tuykhmenev, E., additional, Villevalde, S., additional, Kobalava, Z., additional, Avdoshina, S., additional, Tyukhmenev, E., additional, Efremovtseva, M., additional, Hayashi, H., additional, Suzuki, S., additional, Kataoka, K., additional, Kondoh, Y., additional, Taniguchi, H., additional, Sugiyama, D., additional, Nishimura, K., additional, Sato, W., additional, Maruyama, S., additional, Matsuo, S., additional, Yuzawa, Y., additional, Geraldine, D., additional, Muriel, F., additional, Alexandre, H., additional, Eric, R., additional, Fu, P., additional, Pozzato, M., additional, Ferrari, F., additional, Cecere, P., additional, Mesiano, P., additional, Vallero, A., additional, Livigni, S., additional, Quarello, F., additional, Hudier, L., additional, Decaux, O., additional, Haddj-Elmrabet, A., additional, Mandart, L., additional, Lino-Daniel, M., additional, Bridoux, F., additional, Renaudineau, E., additional, Sawadogo, T., additional, Le Pogamp, P., additional, Vigneau, C., additional, Famee, D., additional, Koo, H. M., additional, Oh, H. J., additional, Han, S. H., additional, Choi, K. H., additional, Kang, S.-W., additional, Mehdi, M., additional, Nicolas, M., additional, Mariat, C., additional, Shah, P., additional, Kute, V. B., additional, Vanikar, A., additional, Gumber, M., additional, Patel, H., additional, Trivedi, H., additional, Manetos, C., additional, Poulaki, S., additional, Tripodaki, E.-S., additional, Papastylianou, A., additional, Routsi, C., additional, Uchida, K., additional, Kensuke, U., additional, Yamagata, K., additional, Saitou, C., additional, Okada, M., additional, Chita, G., additional, Davies, M., additional, Veriawa, Y., additional, Naicker, S., additional, Mukhopadhyay, P., additional, Mukherjee, D., additional, Mishra, R., additional, Kar, M., additional, Zickler, D., additional, Wesselmann, H., additional, Schindler, R., additional, Gutierrez*, E., additional, Egido, J., additional, Rubio-Navarro, A., additional, Buendia, I., additional, Blanco-Colio, L. M., additional, Toldos, O., additional, Manzarbeitia, F., additional, De Lorenzo, A., additional, Sanchez, R., additional, Praga^, M., additional, Moreno^, J. A., additional, Kim, M. Y., additional, Kang, N. R., additional, Jang, H. R., additional, Lee, J. E., additional, Huh, W., additional, Kim, Y.-G., additional, Kim, D. J., additional, Hong, S.-C., additional, Kim, J.-S., additional, Oh, H. Y., additional, Okamoto, T., additional, Kamata, K., additional, Naito, S., additional, Tazaki, H., additional, Kan, S., additional, Anne-Kathrin, L.-G., additional, Matthias, K., additional, Speer, T., additional, Andreas, L., additional, Heinrich, G., additional, Thomas, V., additional, Poppleton, A., additional, Danilo, F., additional, Lai, C.-F., additional, Wu, V.-C., additional, Shiao, C.-C., additional, Huang, T.-M., additional, Wu, K.-D., additional, Bedford, M., additional, Farmer, C., additional, Irving, J., additional, Stevens, P., additional, Patera, F., additional, Mattozzi, F., additional, Battistoni, S., additional, Fagugli, R. M., additional, Park, M. Y., additional, Choi, S. J., additional, Kim, J. G., additional, Hwang, S. D., additional, Xie, H., additional, Chen, H., additional, Xu, S., additional, He, Q., additional, Liu, J., additional, Hu, W., additional, Liu, Z., additional, Dalboni, M., additional, Blaya, R., additional, Quinto, B. M., additional, Narciso, R., additional, Oliveira, M., additional, Monte, J., additional, Durao, M., additional, Cendoroglo, M., additional, Batista, M., additional, Hanemann, A. L., additional, Liborio, A., additional, Martins, A., additional, Pinheiro, M. C. C., additional, Meneses, G., additional, De Paula Pessoa, R., additional, Sousa, M., additional, Bezerra, F. S. M., additional, Albuquerque, P. L. M. M., additional, Lima, J. B., additional, Lima, C. B., additional, Veras, M. D. S. B., additional, Nemoto Matsui, T., additional, Totoli, C., additional, Cruz Andreoli, M. C., additional, Vilela Coelho, M. P., additional, Guimaraes de Souza, N. K., additional, Ammirati, A. L., additional, De Carvalho Barreto, F., additional, Ferraz Neto, B.-H., additional, Fortunato Cardoso Dos Santos, B., additional, Abraham, A., additional, Abraham, G., additional, Mathew, M., additional, Duarte, P. M. A., additional, Duarte, F. B., additional, Barros, E. M., additional, Castro, F. Q. S., additional, Palomba, H., additional, Castro, I., additional, Sousa, S. R., additional, Jesus, A. N., additional, Romano, T., additional, Burdmann, E., additional, Yu, L., additional, Kwon, S. H., additional, You, J. Y., additional, Hyun, Y. K., additional, Woo, S. A., additional, Jeon, J. S., additional, Noh, H. J., additional, Han, D. C., additional, Tozija, L., additional, Petronievic, Z., additional, Selim, G., additional, Nikolov, I., additional, Stojceva-Taneva, O., additional, Cakalaroski, K., additional, Lukasz, A., additional, Beneke, J., additional, Menne, J., additional, Schiffer, M., additional, Polanco, N., additional, Hernandez, E., additional, Gutierrez, E., additional, Gutierrez Millet, V., additional, Gonzalez Monte, E., additional, Morales, E., additional, Praga, M., additional, Francisco Javier, L., additional, Nuria, G.-F., additional, Jose Maria, M.-G., additional, Bes Rastrollo, M., additional, Angioi, A., additional, Conti, M., additional, Cao, R., additional, Atzeni, A., additional, Pili, G., additional, Matta, V., additional, Murgia, E., additional, Melis, P., additional, Binda, V., additional, Pani, A., additional, Thome*, F., additional, Leusin, F., additional, Barros, E., additional, Morsch, C., additional, Balbinotto, A., additional, Pilla, C., additional, Premru, V., additional, Buturovic-Ponikvar, J., additional, Ponikvar, R., additional, Marn-Pernat, A., additional, Knap, B., additional, Kovac, J., additional, Gubensek, J., additional, Kersnic, B., additional, Krnjak, L., additional, Prezelj, M., additional, Granatova, J., additional, Havrda, M., additional, Hruskova, Z., additional, Kratka, K., additional, Remes, O., additional, Mokrejsova, M., additional, Bolkova, M., additional, Lanska, V., additional, Rychlik, I., additional, Uniacke, M. D., additional, Lewis, R. J., additional, Harris, S., additional, Roderick, P., additional, Martin, N., additional, Ulrich, K., additional, Jan, B., additional, Jorn, B., additional, Reinhard, B., additional, Jan, K., additional, Hermann, H., additional, Meyer Tobias, F., additional, Leyla, R., additional, Schmidt Bernhard, M. W., additional, Harald, S., additional, Jurgen, S., additional, Tanja, K., additional, Mario, S., additional, Sang Hi, E., additional, Claus, M., additional, Frank, V., additional, Aleksej, S., additional, Sengul, S., additional, Robert, S., additional, Karin, W., additional, Feikah, G., additional, Menne Tobias, F., additional, Meyer Tobias, N., additional, Beutel, G., additional, Fleig, S., additional, Steinhoff, J., additional, Meyer, T., additional, Hafer, C., additional, Bramstedt, J., additional, Busch, V., additional, Vischedyk, M., additional, Kuhlmann, U., additional, Ries, W., additional, Mitzner, S., additional, Mees, S., additional, Stracke, S., additional, Nurnberger, J., additional, Gerke, P., additional, Wiesner, M., additional, Sucke, B., additional, Abu-Tair, M., additional, Kribben, A., additional, Klause, N., additional, Merkel, F., additional, Schnatter, S., additional, Dorresteijn, E., additional, Samuelsson, O., additional, Brunkhorst, R., additional, Stec-Hus Registry, G., additional, Reising, A., additional, Bange, F.-C., additional, Hiss, M., additional, Vetter, F., additional, Bode-Boger, S. M., additional, Martens-Lobenhoffer, J., additional, Schmidt, B. M. W., additional, Kielstein, J. T., additional, Shin, H. S., additional, Jung, Y. S., additional, and Rim, H., additional

Published
2012
Full Text
View/download PDF

13. Paediatric nephrology

Author

Shi, H., primary, Wen, J., additional, LI, Z., additional, Elsayed, M., additional, Kamal, K., additional, Shi, H., additional, El Shal, A., additional, Youssef, D., additional, Caubet, C., additional, Lacroix, C., additional, Benjamin, B., additional, Bandin, F., additional, Bascands, J.-L., additional, Monsarrat, B., additional, Decramer, S., additional, Schanstra, J., additional, Laetitia, D.-B., additional, Ulinski, T., additional, Aoun, B., additional, Ozdemir, K., additional, Dincel, N., additional, Sozeri, B., additional, Mir, S., additional, Berdeli, A., additional, Akyigit, F., additional, Mizerska-Wasiak, M., additional, Panczyk-Tomaszewska, M., additional, Szymanik-Grzelak, H., additional, Roszkowska-Blaim, M., additional, Jamin, A., additional, Dehoux, L., additional, Monteiro, R. C., additional, Deschenes, G., additional, Bouts, A., additional, Davin, J.-C., additional, Dorresteijn, E., additional, Schreuder, M., additional, Lilien, M., additional, Oosterveld, M., additional, Kramer, S., additional, Gruppen, M., additional, Pintos-Morell, G., additional, Ramaswami, U., additional, Parini, R., additional, Rohrbach, M., additional, Kalkum, G., additional, Beck, M., additional, Carter, M., additional, Antwi, S., additional, Callegari, J., additional, Kotanko, P., additional, Levin, N. W., additional, Rumjon, A., additional, Macdougall, I. C., additional, Turner, C., additional, Booth, C. J., additional, Goldsmith, D., additional, Sinha, M. D., additional, Camilla, R., additional, Loiacono, E., additional, Donadio, M. E., additional, Conrieri, M., additional, Bianciotto, M., additional, Bosetti, F. M., additional, Peruzzi, L., additional, Conti, G., additional, Bitto, A., additional, Amore, A., additional, Coppo, R., additional, Maldyk, J., additional, Chou, H.-H., additional, Chiou, Y.-Y., additional, Bochniewska, V., additional, Jobs, K., additional, Jung, A., additional, Fallahzadeh Abarghooei, M. H., additional, Zare, J., additional, Sedighi Goorabi, V., additional, Derakhshan, A., additional, Basiratnia, M., additional, Fallahzadeh Abarghooei, M. A., additional, Hosseini Al-Hashemi, G., additional, Fallahzadeh Abarghooei, F., additional, Kluska-Jozwiak, A., additional, Soltysiak, J., additional, Lipkowska, K., additional, Silska, M., additional, Fichna, P., additional, Skowronska, B., additional, Stankiewicz, W., additional, Ostalska-Nowicka, D., additional, Zachwieja, J., additional, Girisgen, L., additional, Sonmez, F., additional, Yenisey, C., additional, Kis, E., additional, Cseprekal, O., additional, Kerti, A., additional, Szabo, A., additional, Salvi, P., additional, Benetos, A., additional, Tulassay, T., additional, Reusz, G., additional, Makulska, I., additional, Szczepanska, M., additional, Drozdz, D., additional, Zwolnska, D., additional, Tolstova, E., additional, Anis, L., additional, Alber, B., additional, Edouard, B., additional, Gerard, C., additional, Seni, K., additional, Dunia Julienne Hadiza, T., additional, Christian, S., additional, Benoit, T., additional, Francois, B., additional, Adama, L., additional, Rosenberg, A., additional, Munro, J., additional, Murray, K., additional, Wainstein, B., additional, Ziegler, J., additional, Singh-Grewal, D., additional, Boros, C., additional, Adib, N., additional, Elliot, E., additional, Fahy, R., additional, Mackie, F., additional, Kainer, G., additional, Polak-Jonkisz, D., additional, Zwolinska, D., additional, Laszki-Szczachor, K., additional, Janocha, A., additional, Rusiecki, L., additional, Sobieszczanska, M., additional, Garzotto, F., additional, Ricci, Z., additional, Clementi, A., additional, Cena, R., additional, Kim, J. C., additional, Zanella, M., additional, Ronco, C., additional, Purzyc, L., additional, Peco-Antic, A., additional, Kotur-Stevuljevic, J., additional, Paripovic, D., additional, Scekic, G., additional, Milosevski-Lomic, G., additional, Bogicevic, D., additional, Spasojevic-Dimitrijeva, B., additional, Hassan, R., additional, El-Husseini, A., additional, Sobh, M., additional, Ghoneim, M., additional, Harambat, J., additional, Bonthuis, M., additional, Van Stralen, K. J., additional, Ariceta, G., additional, Battelino, N., additional, Jahnukainen, T., additional, Sandes, A. R., additional, Combe, C., additional, Jager, K. J., additional, Verrina, E., additional, Schaefer, F., additional, Espindola, R., additional, Bacchetta, J., additional, Cochat, P., additional, Stefanis, C., additional, Leroy, S., additional, Fernandez-Lopez, A., additional, Nikfar, R., additional, Romanello, C., additional, Bouissou, F., additional, Gervaix, A., additional, Gurgoze, M., additional, Bressan, S., additional, Smolkin, V., additional, Tuerlinkx, D., additional, Stefanidis, C., additional, Vaos, G., additional, Leblond, P., additional, Gungor, F., additional, Gendrel, D., additional, Chalumeau, M., additional, Rawlins, D., additional, Simpson, J. M., additional, Arnaud, G., additional, Anne, M., additional, Stephanie, T., additional, Flavio, B., additional, Veronique, F. B., additional, Stephane, D., additional, Mumford, L., additional, Marks, S., additional, Ahmad, N., additional, Maxwell, H., additional, Tizard, J., additional, Vidal, E., additional, Amigoni, A., additional, Varagnolo, M., additional, Benetti, E., additional, Ghirardo, G., additional, Brugnolaro, V., additional, Murer, L., additional, Christine, G., additional, Degi, A., additional, Szabo, A. J., additional, Reusz, G. S., additional, Vidoni, A., additional, Ramondo, G., additional, and Miotto, D., additional

Published
2012
Full Text
View/download PDF

14. Safety and Efficacy of Cinacalcet in Children Aged Under 3 Years on Maintenance Dialysis.

Author

Bernardor J, Flammier S, Zagozdzon I, Lalayiannis AD, Koster-Kamphuis L, Verrina E, Dorresteijn E, Guzzo I, Haffner D, Shroff R, Schmitt CP, and Bacchetta J

Abstract

Introduction: Secondary hyperparathyroidism (sHPT) is particularly severe in rapidly growing infants in dialysis. Although cinacalcet is effective and licensed in dialysis in children aged >3 years, its efficacy and safety for children aged <3 years is unknown., Methods: We identified 26 children aged <3 years who were on dialysis and treated with cinacalcet between 2009 and 2021 in 8 European pediatric centers., Results: Median (interquartile range) age at the start of cinacalcet was 18 (interquartile range: 11-27) months, serum parathyroid hormone (PTH) was 792 (411-1397) pg/ml, corresponding to 11.6 (5.9-19.8) times the upper limit of normal (ULN). Serum calcium was 2.56 (2.43-2.75) mmol/l, and serum phosphate 1.47 (1.16-1.71) mmol/l. Serum 25-OH vitamin D (25-OHD) was 70 (60-89) nmol/l, 3 children were vitamin D deficient (<50 nmol/l). The initial cinacalcet dose was 0.4 (0.2-0.8) mg/kg/d and the maximum dose was 1.1 (0.6-1.2) mg/kg/d. The median follow-up under cinacalcet was 1.2 (0.7-2.0) years. PTH decreased to 4.3 (2.2-7.8) times the ULN after 6 months, to 2.0 (1.0-5.3) times ULN after 12 months, and to 1.6 (0.5-3.4) times thereafter ( P  = 0.017/0.003/<0.0001, log-transformed PTH). Seven of the 26 infants developed 10 hypocalcemic episodes <2.10 mmol/l. Oral calcium intake was 84% (66%-117%) of recommended nutrient intake at start, 100% (64%-142%) at 3 months and declined to 78% (65%-102%) at 12 months of therapy. Three children developed clinical signs of precocious puberty., Conclusion: Cinacalcet efficiently controlled severe sHPT in children aged <3 years and was associated with hypocalcemic episodes (similar to what is observed in older children) and precious puberty, thereby mandating meticulous control of calcium (considering nutrition, supplementation, and dialysate) and endocrine changes., (Crown Copyright © 2024 Published by Elsevier Inc. on behalf of the International Society of Nephrology.)

Published
2024
Full Text
View/download PDF

15. Clinical Factors and Adverse Kidney Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis.

Author

Marlais M, Wlodkowski T, Printza N, Kronsteiner D, Krisam R, Sauer L, Aksenova M, Ashoor I, Awan A, Bacchetta J, Balasubramanian R, Basu B, Bekassy Z, Boyer O, Chan EY, Csaicsich D, Decramer S, Dorresteijn E, Drozynska-Duklas M, Eid LA, Espinosa L, Ferraris V, Flögelová H, Forero-Delgadillo J, Gianviti A, Gracchi V, González ML, Hansen M, Hattori M, Hong X, Hooman N, Ivanov D, Kang HG, Karava V, Kazyra I, Lungu A, Marks S, Maxted A, Moczulska A, Müller R, Nastausheva T, Parolin M, Pecoraro C, Principi I, Sanchez-Kazi C, Saygili S, Schild R, Shenoy M, Sinha R, Spizzirri AP, Stack M, Szczepanska M, Tsygin A, Tzeng J, Urbonas V, Zapata C, Zieg J, Schaefer F, Vivarelli M, and Tullus K

Subjects
Child, Humans, Kidney, Antibodies, Antineutrophil Cytoplasmic, Glomerulonephritis diagnosis
Published
2023
Full Text
View/download PDF

16. Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study.

Author

Bouwmeester RN, Duineveld C, Wijnsma KL, Bemelman FJ, van der Heijden JW, van Wijk JAE, Bouts AHM, van de Wetering J, Dorresteijn E, Berger SP, Gracchi V, van Zuilen AD, Keijzer-Veen MG, de Vries APJ, van Rooij RWG, Engels FAPT, Altena W, de Wildt R, van Kempen E, Adang EM, Ter Avest M, Ter Heine R, Volokhina EB, van den Heuvel LPWJ, Wetzels JFM, and van de Kar NCAJ

Abstract

Introduction: The introduction of eculizumab has improved the outcome in patients with atypical hemolytic uremic syndrome (aHUS). The optimal treatment strategy is debated. Here, we report the results of the CUREiHUS study, a 4-year prospective, observational study monitoring unbiased eculizumab discontinuation in Dutch patients with aHUS after 3 months of therapy., Methods: All pediatric and adult patients with aHUS in native kidneys and a first-time eculizumab treatment were evaluated. In addition, an extensive cost-consequence analysis was conducted., Results: A total of 21 patients were included in the study from January 2016 to October 2020. In 17 patients (81%), a complement genetic variant or antibodies against factor H were identified. All patients showed full recovery of hematological thrombotic microangiopathy (TMA) parameters after the start of eculizumab. A renal response was noted in 18 patients. After a median treatment duration of 13.6 weeks (range 2.1-43.9), eculizumab was withdrawn in all patients. During follow-up (80.7 weeks [0.0-236.9]), relapses occurred in 4 patients. Median time to first relapse was 19.5 (14.3-53.6) weeks. Eculizumab was reinitiated within 24 hours in all relapsing patients. At last follow-up, there were no chronic sequelae, i.e., no clinically relevant increase in serum creatinine (sCr), proteinuria, and/or hypertension in relapsing patients. The low sample size and event rate did not allow to determine predictors of relapse. However, relapses only occurred in patients with a likely pathogenic variant. The cost-effectiveness analysis revealed that the total medical expenses of our population were only 30% of the fictive expenses that would have been made when patients received eculizumab every fortnight., Conclusion: It is safe and cost-effective to discontinue eculizumab after 3 months of therapy in patients with aHUS in native kidneys. Larger data registries are needed to determine factors associated with suboptimal kidney function recovery during eculizumab treatment, factors to predict relapses, and long-term outcomes of eculizumab discontinuation., (© 2022 Published by Elsevier Inc. on behalf of the International Society of Nephrology.)

Published
2022
Full Text
View/download PDF

17. Crystal clear cerebral ultrasound images mimicking acute asphyxia in an infant with primary hyperoxaluria.

Author

Ardemani G, Govaert P, Oussoren E, Dorresteijn E, Wildschut E, Lequin M, and Dudink J

Subjects
Diagnosis, Differential, Female, Humans, Infant, Magnetic Resonance Imaging, Ultrasonography, Asphyxia Neonatorum diagnostic imaging, Brain diagnostic imaging, Hyperoxaluria, Primary diagnostic imaging
Abstract

Genetic deficiencies in enzymes involved in glyoxylate metabolism lead to primary hyperoxaluria (PH) type I, typically characterized by deposition of oxalate crystals in kidneys. A 2-month-old infant was admitted, and was diagnosed with renal failure. Abdominal ultrasound images revealed enlarged and hyperechoic kidneys. Additionally, on cerebral ultrasound (CUS) hyperechoic changes of thalami and basal ganglia were noted, reminiscent of perinatal hypoxic-ischemic brain damage. However, MRI of the brain did not show any abnormal signal intensities compatible with asphyxia. The hyperechoic appearance of deep grey matter, in particular putamen, was therefore not due to asphyxiated brain damage but seemed related to the deposition of oxalate salts. Moreover, macular crystals were detected at ophthalmoscopy. Our case report shows the potential of US imaging to detect deposition of crystals not only in kidneys but also in brain mimicking, perinatal asphyxia., (Copyright © 2017 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.)

Published
2017
Full Text
View/download PDF

18. [Diagnostic image (272). A boy with discoloured, painful hands].

Author

Bekkali N, Niemantsverdriet MB, and Dorresteijn EM

Subjects
Child, Diagnosis, Differential, Humans, Immersion Foot drug therapy, Male, Treatment Outcome, Amlodipine therapeutic use, Hand pathology, Immersion Foot diagnosis, Vasodilator Agents therapeutic use
Abstract

A 6-year-old boy was admittted because of dark discoloured and painful finger tips of both hands, which had developed 2 weeks after playing with bare hands in a ditch with cold water still containing parts of ice. Trench foot of the hands was diagnosed.

Published
2006

19. [Facial paresis in children; consider Lyme disease].

Author

Dorresteijn EM and Kouwenberg JM

Subjects
Adolescent, Bell Palsy diagnosis, Borrelia burgdorferi Group immunology, Ceftriaxone administration & dosage, Cephalosporins administration & dosage, Child, Child, Preschool, Diagnosis, Differential, Enzyme-Linked Immunosorbent Assay, Female, Fluoroimmunoassay, Humans, Lyme Neuroborreliosis drug therapy, Lyme Neuroborreliosis microbiology, Netherlands, Practice Guidelines as Topic, Borrelia burgdorferi Group isolation & purification, Facial Paralysis microbiology, Lyme Neuroborreliosis diagnosis
Abstract

Three girls, aged 3, 7 and 13 years, developed acute peripheral facial palsy. The first patient was initially diagnosed as having Bell's palsy. The third patient had negative serology at first assessment, on the basis of which the diagnosis of Lyme disease was temporarily rejected. Ultimately, all three appeared to have neuroborreliosis. They were treated with intravenous ceftriaxone and recovered well. Facial palsy in childhood is frequently caused by Lyme borreliosis and infection with Borrelia burgdorferi should therefore be investigated, even if there are no signs of a tick bite or erythema migrans. Diagnosis is made by serology, followed by immunoblotting to confirm a positive result. In case of strong suspicion based on the patient's history or physical examination or a positive serology, lumbar puncture should be carried out. Antibiotic treatment facilitates recovery and prevents complications.

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results